- Poster presentation
- Open Access
Comparison of the inhibitory effects of resveratrol and tranilast on IgE, 48/80 and substance P dependent-mast cell activation
© Catalli et al; licensee BioMed Central Ltd. 2010
Published: 12 May 2010
Several health promoting effects have been attributed to the polyphenol resveratrol including anti cancer, anti-oxidant and anti-inflammatory activities.
We investigated the effects of resveratrol on LAD2 and CD34+-derived mast cell activation in comparison to the known anti-allergy drug tranilast.
Degranulation was quantified by β hexosaminidase assay, and cytokine, chemokine and cysteinyl leukotrienes (cysLT) expression was measured by real time PCR and ELISA. Fura-2 Ca2+ imaging was employed to measure [Ca2+]i.
In LAD2 cells, both resveratrol and tranilast (10 ug/ml) inhibited degranulation induced by mast cell activators IgE/anti-IgE (39% and 19%, respectively; P<0.03), compound 48/80 (9% and 6%), and substance P (23% and 28%; P<0.03). This may be attributable to modulation of Ca2+ levels, as resveratrol, and to a lesser extent tranilast, attenuated substance P-dependent increases in [Ca2+]i. Resveratrol and tranilast blocked cytokine formation, reducing substance P-induced TNF production (65%; P=0.04 and 46%; P=0.09, respectively), but not MCP-1 production. Furthermore, resveratrol inhibited FcepsilonRI mediated production of cysLT by 31% compared to control, whereas tranilast had no effect. The effects of resveratrol on degranulation and release of cysLT were more marked in human primary mast cells (HuMC) (64% and 90% inhibition, respectively; P<0.05), and the polyphenol was found to be significantly more efficacious than tranilast in these cells.
Resveratrol inhibited mast cell function at the level of degranulation, and cytokine and cysLT production, and was comparable, and in some cases, more potent than the anti-allergy drug tranilast. Thus resveratrol may be an effective therapeutic agent for the treatment of allergic disease.
Funded by intramural NRC funds.
This article is published under license to BioMed Central Ltd.